

Rhythm Extends ColoSTAT[®] Clinical Trial to Western Australia

- Perth based CliniTrials joins Rhythm's ColoSTAT[®] Clinical Trial;
- Adds a network of clinicians across Perth and regional WA that reach a large catchment of patients; and
- First patients recruited.

13 April 2021, Melbourne: Rhythm Biosciences (ASX: RHY) is pleased to confirm that CliniTrials, a network of clinicians with a centralised administration, is the latest group to join Rhythm's clinical trial for ColoSTAT[®], a simple blood test for the detection of colorectal cancer, aimed at global mass market screening.

With over 20 years of experience, CliniTrials represent up to six sites in Western Australia which include large patient populations across Perth, Mandurah and Busselton regions. Clinicians at the GP and family practice level are intimately connected with their patients at these locations and are well placed to identify those people that could participate in the trial.

Rhythm CEO, Glenn Gilbert, commented:

"The addition of CliniTrials in Perth further extends the geographic diversification of our clinical trial for our lifesaving colorectal cancer detection technology, ColoSTAT[®].

The technology that underpins ColoSTAT[®] will transform the way we screen for colorectal cancer globally. We have demonstrated it to be highly accurate, and are focused on working with our partners to complete the clinical trial and deliver ColoSTAT[®] to market."

With authority by the Board.

For further information, please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

About Rhythm Biosciences

Rhythm Biosciences (ASX: RHY) is a transformative, predictive diagnostics company, specialising in early cancer detection. Rhythm's initial business pursuit is centred upon technology originally developed by the CSIRO and involves the development and commercialisation of a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Globally, over 850,000 people die from colorectal cancer each year. Colorectal cancer is typically diagnosed at a later stage when there is a poor prognosis for long-term survival. Annual estimated unscreened 50-74-year old's is estimated at +130m for the US, EU and AU alone, with this market potential being more than \$6.5b.